In a patient with persistent lupus anticoagulant positivity and now negative anticardiolipin antibodies, should I continue apixaban (Eliquis)?

Continue Apixaban in LA-Positive, ACLA-Negative Patient

Yes, continue apixaban (Eliquis) in this patient with persistent lupus anticoagulant positivity, as LA positivity alone is sufficient to maintain indefinite anticoagulation for thrombotic APS, regardless of anticardiolipin antibody status. 1

Key Reasoning

LA Positivity is the Critical Factor

The persistent lupus anticoagulant (LA) positivity is what matters most for ongoing anticoagulation decisions, not the anticardiolipin antibody (ACLA) status 1. The 2025 ISTH guidance emphasizes that LA positivity remains the cornerstone laboratory criterion for APS diagnosis and identifies patients requiring long-term anticoagulation 1. The fact that ACLA has become negative does not eliminate the thrombotic risk conferred by persistent LA positivity.

Understanding the Antibody Profile

• Single-positive LA (your patient's current profile) carries lower thrombotic risk than triple-positive APS, but still requires anticoagulation after a thrombotic event 1, 2
• The conversion of ACLA from positive to negative represents a change from double-positive to single-positive LA status
• This does NOT justify stopping anticoagulation, as LA positivity alone is sufficient for APS classification and treatment 2

Important Caveats About Apixaban and LA Testing

Testing Interference Concerns

Critical pitfall: Apixaban itself can interfere with LA testing, potentially causing false-positive OR false-negative results 3, 4, 5, 6:

• Apixaban causes approximately 2-fold increased likelihood of false-positive LA results 3
• At trough levels, apixaban produces 40% false-positive dRVVT results and 20-30% false-positive aPTT-based LA results 4
• Apixaban affects the confirmatory test more than the screening test, which can paradoxically lead to lower RVVT ratios and potential false-negative LA results 5

Verification Strategy

Before assuming LA is truly persistent, consider:

1. Was the LA testing performed while on apixaban? If yes, the results may be unreliable 1, 6
2. Ideally, LA should be retested after temporary apixaban discontinuation (48 hours for elective procedures per FDA label) 7 or using DOAC removal agents 1, 6
3. If LA remains positive after proper testing off anticoagulation, this confirms true persistent LA positivity

Apixaban vs. Warfarin Considerations

Evidence Limitations

Warfarin remains the gold standard for APS - the FDA label for apixaban does not include APS as an approved indication 7. Available evidence shows:

• A 2022 case series demonstrated VTE recurrence and bleeding complications with apixaban in APS patients 8
• Apixaban has not been adequately studied in controlled trials for APS patients 8
• The ARISTOTLE trial (which established apixaban efficacy) specifically studied atrial fibrillation, not APS 7

When Apixaban May Be Reasonable

Continue apixaban if:

• Patient has documented warfarin failure, intolerance, or inability to maintain therapeutic INR
• Patient refuses warfarin or cannot comply with INR monitoring
• The original thrombotic event was venous (not arterial) - arterial thrombosis in APS has higher recurrence risk with DOACs
• Patient is NOT triple-positive (your patient meets this criterion)

When to Switch to Warfarin

Strongly consider switching to warfarin if:

• Patient has had arterial thrombosis (stroke, MI)
• Patient develops recurrent thrombosis on apixaban
• Patient was originally triple-positive (even if ACLA now negative, the LA remains positive)

Monitoring Plan

While continuing apixaban:

1. Clinical surveillance: Monitor closely for any signs of recurrent thrombosis
2. Bleeding assessment: Apixaban carries bleeding risk similar to warfarin 7
3. Retest LA off anticoagulation if clinically feasible to confirm true persistent positivity 1, 6
4. Maintain indefinite anticoagulation - do not stop based on ACLA negativity alone 9

Bottom Line

The persistent LA positivity mandates continued anticoagulation regardless of ACLA status. While warfarin is preferred for APS, continuing apixaban is reasonable if there are compelling reasons to avoid warfarin, particularly if the original event was venous thrombosis and the patient is not triple-positive. However, verify that LA testing was not falsely influenced by apixaban itself, and maintain heightened vigilance for thrombotic recurrence.